CD40LG and glioma: Neither anti-HCMV IgG nor IgM positivity was significantly associated with glioma risk (OR: 1.04, 95% CI: 0.78–1.39, and OR: 0.97, 95% CI: 0.72–1.31, respectively), adjusting for age, sex, and race/ethnicity.